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Abstract: Treating chronic pain in the context of opioid misuse can be very challenging. This 
paper explores the epidemiology and potential treatments for chronic pain and opioid misuse and 
identifies educational and regulation changes that may reduce diversion of opioid  analgesics. We 
cover the epidemiology of chronic pain and aberrant opioid behaviors, psychosocial influences 
on pain, pharmacological treatments, psychological treatments, and social treatments, as well as 
educational and regulatory efforts being made to reduce the diversion of prescription opioids. 
There are a number of ongoing challenges in treating chronic pain and opioid misuse, and more 
research is needed to provide strong, integrated, and empirically validated treatments to reduce 
opioid misuse in the context of chronic pain.
Keywords: addiction, dependence, diversion, comorbid, narcotic, treatment
Introduction
Opioid analgesics remain the mainstay of pharmacologic treatment for acute and 
chronic pain. However, the risks for misuse and development of addiction have 
raised concerns for clinicians, public health specialists, and the community at large. 
The concern about prescription drug addiction has resulted in new state and federal 
 policies and monitoring systems, and yet there is a need to help the increasing number 
of Americans suffering from chronic pain. The number of prescriptions for opioid 
analgesics has risen dramatically over the last decade,1 and at the same time, reports 
of misused or abused opioids have led to increasing concerns about diversion of these 
potent drugs.2,3
Although the administration of opioids in the management of acute pain carries little 
risk, long-term use of opioid analgesics is associated with clinically relevant rates of 
abuse or addiction. This review will focus on the relationship between  noncancer pain, 
opioid analgesics, opioid misuse, and the diversion of these narcotics. Pharmacotherapy 
and psychosocial treatment strategies for prescription drug addiction and pain manage-
ment are reviewed, including broader policy strategies.
Epidemiology of pain and addiction
It is estimated that up to 50% of Americans experience chronic pain or intermittent 
repeating pain during their lifetime.4 There is an ongoing, and often heated,  discussion 
about how to best treat pain disorders and the role that opioid analgesics should play 
in the treatment of nonmalignant pain to balance the need for pain management 
and the risk of developing an addiction. Despite this ongoing debate, the number of 
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 prescriptions for opioid analgesics is on the rise.1  According 
to the National Ambulatory Medical Care Survey,5 pain 
 complaints account for more than 40% of all symptoms 
related to outpatient visits, or over 100 million ambulatory 
encounters in the US alone each year. Pain costs the US over 
$100 billion per year in health care and lost productivity.6 Fur-
thermore, pain medications are the second most  commonly 
prescribed class of drugs, accounting for 12% of all medica-
tion prescribed during ambulatory office visits in the US.7 
This medical use of opioids, that increased during the 1990s 
in response to an effort to promote better pain control, has 
also been associated with a dramatic increase in the abuse 
of opioids that now seems to be stable.8 Since 1997, the 
four primary opioids used in pain treatment have increased 
markedly, ie, morphine (73%), hydromorphone (96%), fen-
tanyl (226%), and oxycodone (403%).9
Concerns about diversion and addiction are also on 
the rise, as there are an increasing number of reported 
cases of misuse or abuse of opioids.2,3 However, there is 
significant disagreement about the frequency of opioid 
abuse/dependence that occurs due to prescribing for pain, 
with estimates ranging from a low of 3% to a high of 30% 
depending on the study and the methodology used.9,10 A 
recent large scale meta-analysis by Fishbain et al11 studied 
 aberrant drug-related behaviors in the context of chronic 
opioid analgesic therapy. Aberrant behaviors may include 
taking medications off schedule, hoarding medications, 
requesting opioid analgesic refills early, taking too much or 
too little of the prescribed medication, or supplementing with 
nonprescribed drugs (legal or illicit). The results suggest that 
the onset of actual addiction after starting opioids for pain 
management is relatively low (0.19%–3.2%). However, the 
occurrence of aberrant drug-taking behaviors is much higher 
(11.5%). When analyzing only those studies that included a 
urinary toxicology screen, the aberrant drug-related behavior 
rate went even higher, with 20.4% of patients having no 
opioids in their urine screen, and 14.5% testing positive for 
other illicit drugs.11
While the likelihood of patients progressing from taking 
legitimately prescribed opioids for pain to opioid addiction 
is low, pain in the context of pre-existing opioid addiction is 
extremely high. A recent study of pain in the context of opioid 
addiction found that 80% of patients entering methadone 
maintenance treatment reported experiencing frequent 
pain. Approximately 37% of individuals entering for opioid 
addiction reported chronic pain compared with only 24% in 
a general substance abuse population.12 Among individuals 
entering methadone maintenance treatment for addiction 
who experience pain, 65% report moderate to severe pain, 
and pain that interferes with daily activities.12
Among individuals with comorbid opioid addiction and 
chronic pain, pain can significantly interfere with relapse after 
opioid addiction treatment. The odds of opioid relapse after 
detoxification in those with opioid addiction and moderate 
pain are 2.6 times higher than those without pain. Individuals 
with severe pain in the context of opioid addiction have over 
five times higher relapse rate compared with their nonpain 
counterparts with opioid addiction.13
Therefore, while conversion rates to addiction appear to 
be low among individuals starting opioid analgesic therapy 
for chronic pain, aberrant behaviors are not infrequent. 
 Further, among those individuals with comorbid opioid 
addiction and pain, untreated pain can significantly hamper 
recovery from opioid addiction.
According to the Centers for Disease Control and 
 Prevention, deaths from unintentional overdoses are now the 
second leading cause of accidental death in the US. After a 
steep rise beginning in the early 1990s, over 27,000 such 
deaths were recorded in 2007. Nearly 11,500 deaths from 
opioid analgesics in 2007 have contributed to this trend. 
Admissions to drug treatment programs increased by 400% 
between 1998 and 2008; opioid analgesics were the second 
most prevalent abused substance, after marijuana.14 Visits to 
emergency departments for opioid abuse more than doubled 
between 2004 and 2008. National prescription tracking 
data demonstrate that 40% of opioid prescribing is done by 
 family practitioners, osteopaths, or internists, most frequently 
for musculoskeletal complaints. Approximately 3% of the 
US adult population receives long-term opioid therapy for 
chronic noncancer pain.14
These events parallel an increase in the medical use of 
opioids since 1990. Two events conspired to produce this surge 
in opioid prescribing. First, aggressive, and ultimately illegal, 
marketing of OxyContin® began in 1995 following approval of 
the drug. Second, physicians have been encouraged to identify 
and ultimately treat acute and chronic pain. Sales of methadone 
and oxycodone quadrupled between 1997 and 2002.14 
Interestingly, the number of opioid prescriptions correlated 
strongly with mortality, in that, states with the highest 
opioid prescribing rates had the highest rates for accidental 
opioid death. In general, per capita sales are most strongly 
associated with oxycodone-related and methadone-related 
mortality. In almost every sample, men have higher death 
rates than women, most commonly those aged 45–54 years. 
Caucasians and Native Americans have higher death rates 
following overdose than African Americans.14
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Psychosocial influences of pain
Pain is a multidimensional construct that is influenced by 
biological, psychological, and social factors.15 Multiple 
researchers have identified that the perception of pain does 
not correlate well with physical injury,16 and that nonphysical 
forms of pain can activate the same areas of the brain as 
physically induced pain.17 Further, research has indicated that 
descending pathways from the brain can be used to modulate 
(up or down) the messages of the ascending neural pathways.15 
This suggests that the patient is an active  interpreter of the 
pain sensation. The patient filters nerve sensations from the 
body through cultural, emotional, and personal lenses to 
identify if the pain exceeds the patient’s ability to tolerate 
the pain and the need to access treatment.18
A number of psychological factors have been shown 
empirically to alter a patient’s pain experience. Emotional 
status can have a significant impact on a patient’s pain 
experience. Research has identified that depression and 
chronic pain share many of the same serotonergic pathways 
and are a frequent comorbidity.19 Even brief mood states 
can have a significant impact on pain tolerance such that a 
5-minute induced mood state (positive or negative) can alter 
pain tolerance.20 Emotional catastrophizing is strongly 
associated with increased reports of pain and decreased pain 
tolerance.21 Feelings of pain-related self-efficacy can improve 
pain tolerance.22 Patients who feel more in control of their 
pain and have more coping skills with which to tolerate pain 
decrease their negative affect related to pain. In essence, the 
messages patients give themselves about their ability to cope 
with a certain level of pain become a self-fulfilling prophecy. 
These issues are best addressed with a pain psychologist to 
help patients develop their psychosocial pain-coping skills. 
Through psychotherapy, patients can acquire the pain coping 
skills necessary to increase their ability, and their confidence 
in that ability, to tolerate pain. In turn, reliance on pharma-
cotherapy is likely to decrease.
Diagnostic issue: comorbid 
addiction and pain
The prevalence of opioid addiction in chronic nonmalignant 
pain patients have been reported to vary from none in 
some studies up to 50%, and in cancer patients up to 7.7% 
depending on the subpopulation studied and the criteria 
used. Unfortunately, in the research literature, the concept of 
“addiction” is often intertwined with what is better referred to 
as “aberrant drug-related behaviors”. Aberrant drug-related 
behaviors may be red flags, but do not by themselves indicate 
the presence of addiction, which is defined as seeking the 
psychological effects of the drug. Aberrant drug-related 
behaviors can also be indicative of iatrogenic drug-seeking 
behaviors or diversion, among other possibilities. The risk of 
addiction to opioid analgesics needs to be thoroughly evalu-
ated when initiating long-term opioid treatment. Only some 
screening tools like the Pain Medicine Questionnaire23 have 
been thoroughly validated. The risk of developing behavioral 
problems with chronic opioid analgesic therapy varies. While 
some researchers estimate that up to 24% of patients with 
chronic pain develop aberrant drug-related behaviors,24 others 
estimate that these behaviors are higher (50%).25
The commonly used Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition criteria may overestimate 
the problem by using the criteria of tolerance and withdrawal. 
Using varying terms for the evaluation of addiction, such 
as drug-seeking behavior, addictive behavior, and abuse 
behavior can be misleading. Therapeutic dependence is 
another concept that may be present in chronic pain patients 
receiving adequate relief by opioids. These patients tend to 
hoard opioid analgesics to ensure that they continue to obtain 
adequate pain control by building up a personal reserve of 
opioids.26–28
Prospective studies using appropriate and thoroughly 
validated criteria are needed in order to make precise 
conclusions because estimates of addiction problems among 
chronic nonmalignant pain patients on long-term opioid 
treatment have been found to vary significantly. Some patients, 
especially those on short-acting opioids, may suffer from 
recurrent subtle withdrawal, which can be manifested as 
increased pain.29 It may be difficult to differentiate between the 
primary pain and the pain resulting from opioid withdrawal. 
Patients who increase opioid doses for pain relief may actually 
be treating their withdrawal phenomenon.30 To assist clinicians 
in diagnosing addiction in the context of treatment with opioid 
analgesics, Portenoy31 suggested a set of criteria that may be 
useful for this purpose. They recommended assessment of: 
manipulation of the treating physician or medical system for 
the purpose of obtaining additional medication; acquisition 
of medication from other medical or nonmedical sources; the 
tendency to hoard medications or to sell; and unapproved use 
of other drugs, such as alcohol and other sedatives/hypnotics 
during opioid therapy. For example, Dunbar and Katz 32 assessed 
the prevalence of six behavioral criteria of 20 opioid-treated 
patients with chronic pain and addiction problems. They found 
that unauthorized dose escalation, frequent telephone calls, 
receiving opioids from other providers, losing the prescription, 
multiple reported drug allergies, and patient resistance to 
changing opioid medications were well correlated with a 
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behavioral activation, but it occurs on the first visit. The 
patient’s ability to accomplish those goals then indicates if 
the prescribed pharmacological treatment was helpful or if the 
side effects decreased the patient’s ability to accomplish the 
goals. With each appointment, the patient and provider assess 
the patient’s ability to complete the goals established at the 
previous appointment. No dosage increase is made without 
the patient showing progress in meeting their objectives at the 
previous level. This changes the entire focus of the treatment 
plan, ie, rather than focusing on the patient being pain-free, the 
focus is on helping the patient return to his/her daily activities. 
The return to daily activities will have the secondary impact 
of counteracting many mental and physical comorbidities of 
pain, such as depression, social isolation, and weight gain.
Pharmacological treatment
Pharmacological treatment for opiate addiction in the context 
of treating chronic pain is a challenging endeavor. An initial 
comprehensive assessment of each individual case may 
help design a tailored treatment plan that balances effective 
pharmacological treatment for both addiction and pain (see 
Table 1). Recent reformulations of some opioid analgesics 
Table 1 Analgesic agents
Agent Class Mechanism 
of action
Miscellaneous 
facts
Morphine Opiate MOR agonism  
Codeine Opiate MOR agonism Analgesia due to CYP 2D6 metabolism to 
morphine (slow and rapid metabolizers)
Fentanyl Opioid MOR agonism Potent; associated with chest wall rigidity
Hydrocodone Opioid MOR agonism Coformulated with acetaminophen (vicodin®)
Oxycodone Opioid MOR agonism Coformulated with acetaminophen (Percocet®) 
extended-release formulation (Oxycontin®)
Methadone Opioid MOR agonism Long-acting oral agent (.12 hours) 
associated with QTc prolongation
Buprenorphine Opioid MOR agonism Coformulated with naloxone (Suboxone®); 
long-acting and slow time to receptor 
dissociation
Tramadol Opioid MOR agonism 
vs unknown
Associated with seizures
Duloxetine SNRi Unknown Possible serotonin syndrome
Pregabalin Anticonvulsant voltage-gated calcium 
ion channel binding
Gabapentin  Unknown
Milnacipran SNRi NMDA receptor antagonist
Sodium oxybate
Naltrexone  
(low-dose)
Opioid Opioid receptor competitive  
antagonist
Pramipexole Dopaminergic 
agent
D2, D3, D4 receptor binding
Delta-9-THC Cannabinoid Cannabinoid receptor agonism
Abbreviations: CYP, cytochrome P450; MOR, μ opioid receptor; NMDA, N-methyl-D-aspartate; SNRi, serotonin-norepinephrine reuptake inhibitor; QTc, corrected QT 
interval.
diagnosis of addiction made during the course of therapy by 
the patient’s pain physician.
Assessment of pain
Pain is difficult to assess, particularly in the context of addic-
tion, where other multiple factors may be driving elevated or 
suppressed reports of pain. Therefore, the commonly used 
0–10 pain scale is a good start. However, it is not enough to 
base pain treatment on this single self-reported pain measure, 
particularly if the prescriber has concerns about potential 
opioid misuse.
Instead, a functional assessment of pain and pain manage-
ment is a more objective and reliable means to help patients 
address their pain management goals. This type of assessment 
should be used in the first meeting with a  prescriber, and 
may be useful if assisted by a pain psychologist. In this form 
of assessment, the patient and provider identify areas in a 
patient’s life that have been negatively impacted by pain 
management. The provider and patient would then list three 
goals that the patient would be able to accomplish if they 
experienced less pain. In this treatment modality, the provider 
and patient do not wait until the patient is pain-free to begin 
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approved by the US Food and Drug Administration (FDA), ie, 
OxyContin, can potentially reduce the misuse of oral medica-
tions by crushing or creating intravenous preparations.33
Most patients with chronic pain will already be treated 
with an opioid analgesic, and the current clinical strategies 
to treat this comorbidity are frequently geared towards 
conversion to a long-acting μ agonist treatment such as 
methadone, treatment with a partial μ agonist such as 
buprenorphine, discontinuation of opioid agonist treatment 
when opioid-induced hyperalgesia develops, and to minimize 
the diversion.
Opioid analgesics
Opiates refer to naturally occurring products that come 
directly from the opium poppy, such as morphine, codeine, 
and thebaine.34 Opioids are agents that bind to central and 
peripheral opioid receptors or produce clinical effects like 
those of natural opium (eg, mimicking opiates). In part, 
these G protein-coupled receptors may regulate analgesia 
via a neurotransmitter (eg, gamma aminobutyric acid) and 
substance P inhibition.35–37 The principle opioid receptors 
include the μ opioid receptor, the κ opioid receptor, the δ opi-
oid receptor, and the opioid receptor-like receptor.36,38 Other 
poorly characterized opioid receptors include ε, ι, λ, and ζ.36 
Anatomic location and receptor specificity determine the type 
and extent of the manifested clinical effect. For example, μ 
opioid receptors in the brain and gut are responsible for anal-
gesia and gastrointestinal dysmotility, respectively. However, 
respiratory depression may result from multiple receptors 
located both centrally and peripherally.37,39–41
Furlan et al42 conducted a meta-analysis of opioids 
for chronic noncancer pain to assess the efficacy of this 
treatment. The analysis included 41 trials involving 6019 
patients, where 80% of the patients had nociceptive pain, 
12% had neuropathic pain, 7% had fibromyalgia, and about 
1% had mixed origin pain. The medications that had been 
evaluated in these trials included tramadol, propoxyphene 
or dextropropoxyphene, codeine, oxycodone, and morphine. 
Interestingly, the average duration of treatment was 5 weeks, 
with 33% of participants dropping out in the opioid-
treated group compared with 38% of participants in the 
placebo groups. The magnitude of pain reduction with 
opioid analgesics compared with placebo was found to be 
moderate and the improvement in functional outcomes was 
even smaller. Eight trials that compared opioids with other 
analgesics showed that opioids did not differ significantly 
from nonopioid analgesics for pain treatment. Interesting, 
opioids were significantly worse than nonopioid analgesics 
on functional improvement measures. Despite the empirical 
evidence that opioid analgesics are not highly efficacious 
for the control of chronic pain and for functional recovery, 
physicians continue to prescribe them. This leads to a number 
of interesting points of discussion that should certainly be 
addressed in a different venue.
Risk and adverse effects of opioids
The sine qua non of opioid toxicity is respiratory depression, 
and other effects, such as miosis, decreased bowel motility, 
and mental status depression, are also problematic side 
effects. Patients with severe respiratory depression require 
supportive care, but antidotal treatment for opioid overdose 
is pharmacologically directed toward antagonizing central 
nervous system opioid receptors. Naloxone (Narcan®) is 
the parenterally available opioid receptor antagonist used in 
clinical practice to reverse the symptoms of opioid-induced 
respiratory depression rapidly.43 Carefully titrated doses 
of naloxone may reverse opioid toxicity without inducing 
symptoms of opioid withdrawal, even in the opioid-dependent 
patient. Assistance in titrating naloxone dosing may be 
obtained from local toxicology consultation services or by 
contacting a poison control center.
Moore and McQuay44 conducted a systematic review 
of 34 trials involving a total of 4212 patients and provided 
information on adverse events related to opioid analgesic 
use in treating noncancer pain. The most frequent side 
effects related to treatment with opioid analgesics compared 
with nonopioid analgesics were nausea, constipation, and 
somnolence. Eisenberg et al45 also reported that treatment 
involving the use of opioid analgesics for neuropathic pain 
when compared with treatment with placebo showed higher 
rates of nausea, constipation, drowsiness, dizziness, and 
vomiting. Endocrine abnormalities, such as hypogonadism 
and erectile dysfunction, may also be associated with 
opioid treatment.46 Opioid treatment may be associated 
with impaired neuropsychological performance, mainly in 
reaction times, psychomotor speed, and working memory.25 
Prolonged treatment with opioid analgesics commonly 
results in the development of opioid-induced hyperalgesia 
that occurs when the balance between antinociceptive 
and pronocioceptive systems are upregulated after opioid 
exposure, with enhanced vulnerability to experience pain.47
Opiates
Morphine is a natural product that produces effective 
analgesia following multiple routes of administration.48 
Decreased analgesia observed following enteral absorption 
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is due to first-pass metabolism that is absent following 
parenteral delivery. Hepatic metabolism results in 
morphine-3-glucuronide and morphine-6-glucuronide, 
and these metabolites are renally excreted.49 Analgesia is 
a consequence of μ opioid receptor agonism centrally and 
peripherally.48,50
Codeine, the biosynthetic precursor to morphine, is 
another natural product used in clinical practice. Codeine 
has no intrinsic analgesic properties; its demethylation to 
morphine via cytochrome P450 (CYP) 2D6 explains the 
absence of clinical effects in specific subpopulations with 
CYP2D6 deficiency.51
Fentanyl
Fentanyl is a highly potent, short-acting synthetic opioid.52 
It exerts clinical effects following multiple routes of 
administration, including transdermal patches, oral lollipops, 
and dissolving lozenges, as well as intravenous administration. 
Fentanyl has found extensive use in the management of 
chronic pain; extended-release formulations are often used 
to treat persistent symptoms, while breakthrough pain may 
be treated with “lollipop” or lozenge formulations. Fentanyl 
has a high abuse potential and has been strongly associated 
with death following misuse.53
Hydrocodone and oxycodone
Hydrocodone and oxycodone are both synthetic opioids 
with intermediate durations of action. Hydrocodone is 
most commonly available orally when coformulated with 
acetaminophen. Oxycodone can be formulated by itself as a 
short-acting medication or as a controlled-release preparation 
(OxyContin) and can also be coformulated with nonsteroidal 
anti-inflammatory agents. Oxycodone has a high potential 
for abuse, has been heavily diverted to illicit purposes, and 
has been associated with many opioid-related overdoses.54 
Because oxycodone can be abused by ingestion, insufflation, 
and parenteral injection, the FDA recently approved a refor-
mulation of OxyContin that mitigates its abuse potential.33
Methadone
Methadone is a synthetic, potent μ opiate receptor agonist and 
is likely the best candidate to achieve the two goals of treating 
pain and addiction. Methadone is 80% bound to blood 
proteins and has a long elimination half-life (24–36 hours), 
facilitating its use for once-daily agonist maintenance in 
the treatment of addiction.55 Dividing the daily dose of 
methadone may help achieve better analgesia and should 
be considered for patients with comorbid chronic pain and 
addiction.56 The methadone maintenance dose for substitution 
therapy is usually 60–150 mg per day. These dosages are 
usually higher among patients with chronic pain, and doses 
up to 300 mg have been reported.57,58
High doses of methadone (.100 mg/day) have been 
associated with cardiac side effects, including QT inter-
val prolongation.59,60 However, a study by Martell et al61 
showed that, regardless of the level of methadone dose, 
there was a mean 10.8 millisecond increase in the QTc 
interval in patients treated with methadone during induction 
and stabilization (P , 0.001), but none of these patients 
had a clinically significant increase in the QTc interval 
(40  millisecond increase or over 500 milliseconds). In 
addition, a study that evaluated 104 patients treated with 
methadone (median 110 mg/day, range 20–1200 mg/day) 
for comorbid pain and addiction showed that a third of these 
patients had a prolonged QTc, but none had a prolongation 
over 500  milliseconds, suggesting a minimal cardiac risk 
among this patient population.62
Based on these concerns about QTc interval prolongation 
associated with methadone treatment, a group of experts 
issued five recommendations:60 patients should be informed 
about the risk of arrhythmia; history-taking should include 
questions about structural heart disease, arrhythmia, and 
syncope; an electrocardiogram should be performed before 
treatment with methadone in all patients to measure the QTc 
interval, and should be followed with an electrocardiogram 
after 30 days of starting methadone and thereafter annually, 
repeating the electrocardiogram when patients need a dosage 
of methadone over 100 mg/day or present with syncope or sei-
zures; in patients with a QTc interval over 450 milliseconds 
but less than 500 milliseconds, there is a need to increase 
monitoring and to review potential risks and benefits of con-
tinuing treatment with methadone, and when QTc interval 
is greater than 500 milliseconds there is a need to reduce or 
discontinue the dose of methadone, and to review potential 
contributing factors that may be worsening the condition, like 
hypokalemia; and review potential drug–drug interactions 
between methadone and other drugs that either increase QTc 
or increase the level of methadone.
Methadone has been used mostly as a maintenance 
medication for opioid-addicted individuals. In addition 
to functioning as a full agonist at the μ opioid receptor, 
methadone is also an antagonist of the N-methyl d-aspartate 
receptor, which explains the decreased development of 
tolerance.
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It should be noted that patients positive for human 
immunodeficiency virus being treated for comorbid pain 
and addiction with methadone will most likely need 
dose adjustment due to the interaction with CYP3A4.57 
While nevirapine and efavirenz have both been reported 
to reduce plasma methadone levels and induce opioid 
withdrawal symptoms, delavirdine may increase methadone 
concentrations, but this effect is unlikely to be clinically 
significant in most cases. Finally, methadone may increase 
plasma concentrations of zidovudine.63
Methadone is a long-acting opiate that can be substituted 
for short-acting opiates like heroin, morphine, oxycodone, 
hydromorphone, and hydrocodone. Due to cross-tolerance 
effects, methadone effectively reduces the euphoric 
and reinforcing effects of further abuse of short-acting 
opioids. Further, the longer half-life of methadone reduces 
fluctuations in opiate receptor stimulation, decreases 
withdrawal symptoms, and decreases the probability of 
relapse. Dividing the methadone dose prolongs the analgesic 
effect of methadone while reducing the reinforcing effect of 
repeated doses, which can translate into an effective treatment 
for comorbid pain and addiction. Methadone maintenance 
programs continue to be the most structured and effective 
treatment for opiate dependence by decreasing intravenous 
drug use and the risk of transmissible infections.64,65
Unfortunately, these methadone treatment programs are 
not authorized in the US to treat chronic pain patients. The 
major limitation of methadone maintenance programs in this 
context is that they are only licensed to treat opiate addiction, 
and dosage adjustment is only possible in order to stabilize 
opioid craving, withdrawal, or sedation. While in many ways 
this restriction may be seen as appropriate given the lack of 
expertise in pain management, this limitation can be resolved 
by integrating treatment with primary care or by blending 
pain management training into the curriculum of addiction 
psychiatry or addiction medicine programs.
Another limitation in methadone treatment programs is 
the regulatory delay of take-home methadone doses, based on 
complete abstinence, but for patients with comorbid chronic 
pain this delay would not allow for divided doses, at least dur-
ing the initial phase of treatment. Patients with chronic pain 
receive a once-daily dose of methadone for their opiate addic-
tion in these programs, although it is likely that they will still 
need short-acting opioids for breakthrough pain. Ideally, these 
patients would be better served in a pain clinic that could simply 
divide the same methadone dose, which would likely control 
the pain without the need of additional opioid medications.
Methadone maintenance in physicians’ off ices or 
“medical maintenance” is an alternative format for take-home 
methadone doses that has the potential of expanding 
methadone maintenance services for those individuals who 
are psychosocially stable.66–68 This could potentially include 
treatment of those with additional chronic pain and can 
translate in resolving both major limitations to methadone 
maintenance treatment of comorbid pain and addiction. 
However, take-home doses have their own problems in 
these settings, including diversion of methadone to the black 
market and fatalities due to accidental ingestion by minors.69 
Conversely, treatment of these patients outside of substance 
abuse treatment facilities generates another set of problems, 
such as lack of expertise in psychosocial interventions. 
Additionally, treatment providers outside of substance abuse 
clinics are less likely to understand the motivational impact 
of frequent urine samples. Additionally, the few nonaddiction 
treatment providers who do integrate urine samples into their 
treatment plan, may not be aware of the need to use toxicol-
ogy results immediately in the therapeutic context to motivate 
change in behavioral patterns while presenting the results in a 
nonjudgmental way to help build an enduring therapeutic alli-
ance. Mostly, patients with addictive disorders respond well 
to these interventions when they are framed in the context of 
treatment in a nonpunitive manner. The paucity of training in 
pain and addiction makes treatment in conventional settings 
challenging for physicians.
Buprenorphine
Buprenorphine is a high-affinity partial μ opioid agonist 
that is used worldwide either alone or as a combination 
tablet of buprenorphine and naloxone for substitution 
therapy.70 This combination was developed to reduce the 
risk of diversion to illicit intravenous use, because such 
administration would precipitate severe withdrawal in 
an opiate-dependent individual. Buprenorphine, and 
its metabolite norbuprenorphine, achieve steady-state 
concentrations in approximately 8–10 days.71 As a partial 
agonist, buprenorphine has minimal risk of overdose from 
respiratory depression, and higher doses of buprenorphine 
can increase the duration of its effects. Because of its long 
action, buprenorphine can be effectively administered in 
alternate day dosing and as infrequently as three times 
per week.72,73 Buprenorphine has a ceiling effect on its 
agonist activity, which may also limit its abuse liability74,75 
and can lead to low toxicity even at high intravenous 
doses.76,77 Buprenorphine is thought to exhibit a ceiling 
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effect on respiratory depression at therapeutic dosing, but 
the impact on supratherapeutic doses of buprenorphine 
has not yet been established. Apnea has been observed 
following polysubstance use (most commonly with misused 
benzodiazepines) and in children, and may occur following 
overdose of buprenorphine itself.
Buprenorphine has the general structure of morphine 
but differs from morphine in significant ways, both phar-
macologically and clinically. A number of long-term studies 
have shown effective, long-lasting analgesia in moderate to 
severe cancer and noncancer pain, including neuropathic 
pain, with a low incidence of constipation, nausea, dizziness, 
and tiredness.
In 2007, a panel of experts specializing in palliative 
care and pain treatment78 reviewed the clinical experience 
with transdermal buprenorphine and other analgesics, and 
considered that transdermal buprenorphine was a valuable 
treatment for cancer pain, including its neuropathic compo-
nents. Buprenorphine has been described to exert an anti-
hyperalgesic effect. The dose range of 35–140 μg per hour 
was considered adequate to achieve sufficient pain relief in 
most patients, although higher doses provided improved pain 
relief when a slow titration was used. Because of the high 
affinity to the μ receptor and its ceiling effect, treatment with 
buprenorphine-naloxone (Suboxone®) maintenance therapy 
may pose at least theoretical problems in managing pain in 
these comorbid patients.79 However, the pharmacological 
profile of buprenorphine, as a partial μ opioid agonist and 
a κ opioid antagonist, makes it an excellent medication for 
the treatment of chronic pain when utilizing a 72-hour trans-
dermal delivery system designed to release buprenorphine 
continuously at 35, 52.5, or 70 μg per hour.80 Buprenorphine 
at lower dosages (0.3–0.6 mg) than those used for the treat-
ment of opioid addiction (12–32 mg) may have excellent 
analgesic effects, but may not have appropriate efficacy for 
opiate addiction. Conversely, because buprenorphine binds 
strongly to opioid receptors, the use of supplementary opioids 
for analgesia is difficult. Therefore, for additional analgesia, 
or breakthrough pain, it may be necessary to force a change 
of treatment with buprenorphine to methadone for mainte-
nance medication.
Patients treated with buprenorphine for addiction can usu-
ally be stabilized with sublingual doses of 12–16 mg per day. 
Ling et al81 showed that patients maintained on buprenorphine 
8–16 mg per day during a 16-week trial were more likely 
than patients maintained on buprenorphine 1 mg per day 
to remain in treatment. In another study, heroin-dependent 
patients without psychiatric or substance use comorbidities 
were successfully treated with buprenorphine at 24 mg on 
Monday and Wednesday, and 36 mg on Friday.82
Tramadol
The mode of action of tramadol is not completely understood, 
but it appears to exert an analgesic effect through binding 
to the μ opioid receptor as a partial agonist. It also inhibits 
the reuptake of serotonin and norepinephrine, and can cause 
serotonin syndrome. Furthermore, tramadol is a proconvul-
sant and has been associated with seizures even at thera-
peutic levels. Tramadol has proven efficacy in fibromyalgia, 
osteoarthritis, and neuropathic pain. Because tramadol is an 
unscheduled drug, clinicians may not be aware of its opioid 
effect and potential for abuse. A randomized trial in patients 
suffering from chronic noncancer pain compared the abuse 
potential of tramadol, nonsteroidal anti-inflammatory drugs, 
and hydrocodone.23 The abuse liability over 12 months was 
0.5%–2.5% for the nonsteroidals, 0.7%–2.7% for tramadol, 
and 1.2%–4.9% for hydrocodone. In another study, McDi-
armid et al83 found that tramadol showed a milder degree 
of physical dependence, but also showed craving during 
discontinuation. Daily recommended doses of tramadol 
should not exceed 400 mg. During discontinuation, gradual 
dose reduction is recommended in elderly populations, and 
in those with renal and hepatic impairment.84
Discontinuation of opioid agonists
The decision to discontinue methadone treatment for opioid 
addiction after a determined length of maintenance is highly 
controversial, given the high risks of relapse to previous 
patterns of maladaptive drug use and the associated morbid-
ity and mortality.85 This also applies to patients treated for 
chronic pain who may be stable and responding well to pain 
management with opioid medications. However, if opioid-
induced hyperalgesia develops in the context of treatment 
for both disorders, it may be necessary to consider discon-
tinuation. The efficacy of long-term treatment for chronic 
pain with opioids is not clearly supported.24 Therefore, 
differentiating between increased tolerance vs sensitization 
to hyperalgesic opioid effects is a key element in the man-
agement of these complications.86 An increase of the dose 
will reduce pain in the context of increased drug tolerance, 
but the same dose increase can potentially aggravate pain 
in the context of sensitization or hyperalgesia. A clarified 
diagnosis helps to individualize treatment and to offer a 
tailor-made management plan, with close monitoring and 
additional psychotherapy to support both pain reduction and 
relapse prevention.
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Nonopioid medications used  
as analgesics
The long-term trajectory of chronic pain that may have pro-
moted the development of opioid addiction can be prognosti-
cally improved if nonopioid agents are effectively used early 
in treatment. Some of these medications can be utilized for 
breakthrough pain, hyperalgesic rescue, or as an adjunct to 
opioid treatment. Most studies support adjunctive medication 
usage in both neuropathic and fibromyalgic pain.
Gabapentin
Gabapentin was initially marketed as an anticonvulsant 
medication, but was later found to be useful in the treatment 
of pain. A recent study showed that gabapentin could be an 
option in the conservative management of acute or chronic 
radicular pain caused by lumbar disc herniation or lumbar 
spinal stenosis.87 In another study, Ucak et al88 compared 
gabapentin with placebo and showed that gabapentin signifi-
cantly reduced the intensity of pain and tramadol consump-
tion relative to placebo when used in the early postoperative 
period after coronary artery bypass graft surgery. The use of 
gabapentin combined with donepezil as an adjunct for the 
treatment of neuropathic pain showed a 3–4-fold increase 
of analgesic effect when compared with treatment using 
gabapentin alone.89 Taken together, these results suggest that 
gabapentin may have a role in the treatment of pain.
Pregabalin
Originally developed as an anticonvulsant, pregabalin 
became the first FDA-approved drug for the treatment of 
fibromyalgia in June 2007. This adjuvant analgesic exerts its 
therapeutic effects by binding to and decreasing the activity 
of the alpha-2-delta subunit of the voltage-gated calcium ion 
channel, which plays an important role in nociceptive hyper-
sensitivity. Presynaptic binding to voltage-gated calcium ion 
channels results in a decrease in excitatory neurotransmitter 
release of neurochemicals, such as substance P, calcitonin, 
and glutamate.90
Pregabalin has been found to be effective in both neu-
ropathic pain and fibromyalgia. Its efficacy in the treatment 
of fibromyalgia has been evaluated in four randomized, 
double-blind, placebo-controlled trials.90–93 The results of 
these studies have consistently shown improvement in pain, 
fatigue, and sleep difficulties, with no major side effects. 
Pregabalin administered at 450 mg/day in three divided doses 
was found to reduce pain scores significantly and increase 
the responder rate compared with placebo during an 8-week 
study, and these changes were independent of improvements 
in levels of anxiety or depression.90
No pharmacokinetic interactions were seen during the 
coadministration of pregabalin and oxycodone, lorazepam, 
or ethanol.94,95 Additive effects on cognitive and gross motor 
functioning were observed, suggesting a need for dose reduc-
tion when combined with benzodiazepines or alcohol. Dose 
reduction is necessary in renal dysfunction, with a need for 
monitoring of creatinine clearance.94,95 There is one report 
by Filipetto et al96 mentioning the potential for pregabalin 
abuse or diversion, based on a single case of a woman who 
received a total of 88,500 mg of pregabalin over a 28-day 
period from different providers.
Duloxetine
Duloxetine is a serotonin-norepinephrine reuptake inhibi-
tor that also has a low affinity for the dopamine transporter 
at higher doses. There have been at least five randomized, 
double-blind, placebo-controlled trials97–101 assessing the 
efficacy of duloxetine for fibromyalgia. Although duloxetine 
decreased pain and symptom severity of fibromyalgia in most 
patients, the improvements were only significant in women 
and independent of baseline status for major depressive dis-
order. In a 12-week study, Arnold et al98 examined the effect 
of duloxetine 60 mg given once or twice daily vs placebo in 
354 women with fibromyalgia with or without concurrent 
major depressive disorder. The results showed a significant 
improvement in pain severity and interference scores, and the 
effects on pain reduction were independent of the effect on 
mood and presence of major depressive disorder. In another 
study, Arnold et al102 conducted a pooled analysis of four 
studies, with 26% of the sample diagnosed with comorbid 
major depressive disorder. These participants were randomly 
assigned to received duloxetine 60–120 mg/day or placebo, 
and the results showed that those treated with duloxetine 
had a better reduction of mean 24-hour pain severity, greater 
reduction of fibromyalgia symptoms, and more improvement 
in mood, quality of life, and function relative to placebo.
The side effects of duloxetine are generally dose-related 
and time-limited. According to Greden et al,103 clinical trials 
to date have demonstrated that duloxetine is safe and well 
tolerated in the dose range of 20–120 mg/day for up to 1 
year.100 The side effects often reported are nausea, dry mouth, 
hyperhidrosis, constipation, insomnia, dizziness, headache, 
and fatigue, which led to a premature discontinuation rate 
of 21% in these trials. The CYP1A2 inhibitor, thioridazine, 
should not be coadministered with duloxetine due to the risk 
of serious ventricular arrhythmias and sudden death.94,95 There 
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have been no reported studies to date of the abuse potential 
with this medication.
Milnacipran
Milnacipran is a serotonin-norepinephrine reuptake inhibitor 
approved for the treatment of fibromyalgia. Milnacipran is 
devoid of action at a large array of receptors, but does appear 
to be a noncompetitive N-methyl d-aspartate antagonist.104 
Functional magnetic resonance imaging studies showed an 
increase in activity in the thalamus, caudate nucleus, cingu-
lum, anterior insula, and amygdala following administration of 
milnacipran 100 mg twice daily.105 Nagaoka et al106 found that 
milnacipran improved both pain at 8 weeks and depression at 
4 weeks. Importantly, only patients who were not depressed 
at the end of the study exhibited significant improvements 
in visual analog score for pain. In a European study, Branco 
et al107 found that milnacipran 200 mg/day for fibromyalgia 
showed an overall improvement in pain and functioning rela-
tive to treatment with placebo. Yet another multicenter study 
in the US showed that significant reductions in pain occurred 
with twice-daily but not with once-daily dosing.108
Milnacipran is well tolerated, but has an adverse event 
profile of nausea, headache, tachycardia, and hypertension 
typical of the serotonin-norepinephrine reuptake inhibitor 
class. The CYP system is not involved in its metabolism, and 
therefore drug–drug interactions are unlikely.94,103
Tricyclic antidepressants
Tricyclic antidepressants are also widely used in the treatment 
of chronic pain, particularly neuropathic pain.109 An adequate 
trial is usually 6–8 weeks, although the analgesic affects of 
tricyclic antidepressants often occur faster than the antide-
pressant effects. There is less evidence to support its use in 
musculoskeletal pain or in inflammatory rheumatic diseases. 
Despite their analgesic properties, tricyclic antidepressants 
are also unfortunately well known for their negative effects, 
with 6%–86% of patients reporting adverse effects, including 
dry mouth, constipation, blurred vision, cognitive changes, 
and tachycardia due to the anticholinergic activity of these 
agents.110 Patients may also discontinue due to adverse effects 
related to sedation and weight gain. There are a number of 
excellent indepth reviews of the analgesic properties of 
antidepressants that can be explored more indepth than in 
this venue.109
Emerging treatments
A series of emerging therapies for pain that include 
dopamine agonists, N-methyl-D-aspartate antagonist 
receptor antagonists, sodium oxybate, low-dose naltrexone, 
pramipexole (nonergoline D2, D3, and D4 dopamine receptor 
binding) and delta-9-tetrahydrocannabinol, have proven 
effective in preliminary trials.94 The therapeutic promise of 
the κ opioid receptor agonists has also been recently revived 
by some preclinical trials, as evident from some drugs 
initiating μ opioid signaling such as methadone and fentanyl, 
that recruit arrestin, promote internalization of the receptor, 
and reduce development of tolerance. Morphine does not 
do this. With the new concept of biased agonism, functional 
selectivity, and ligand-directed signaling,111 different agonists 
binding to the same receptor can produce different actions, 
and an analgesic κ opioid that is not involved in arrestin 
recruitment might not produce dysphoria. Such a novel 
ligand in combination with a peripherally restricted κ opioid 
antagonist to block the constipating and diuretic effects, 
might result in the long-sought nonaddictive designer opioid 
analgesic.112 Recently another molecular target for treating 
chronic neuropathic pain was identified. Protein kinase 
M zeta, an atypical isoform of protein kinase C, appears to 
maintain persistent changes in the anterior cingulate cortex 
induced by neuropathic pain, and selective inhibitors of 
protein kinase M zeta could treat this condition.113
Psychosocial approaches  
to treatment
Psychosocial factors should be considered in any assessment 
and treatment of comorbid opioid misuse and pain. 
Psychosocial factors may be one of our strongest weapons 
against abuse and misuse of opioids. Empirically validated 
treatments for this comorbidity are in the early stages of 
development. We will review the literature on what treatment 
approaches are individually validated for the treatment of pain 
or addiction, and where there is empirical evidence to support 
their use in treatment of comorbid pain and addiction.
Motivational interviewing
Clinicians who work with pain patients and suspect opioid 
misuse should be familiar with the techniques of motivational 
interviewing. During a motivational interview, clinicians 
draw on the transtheoretical stages of change developed by 
Prochaska and Diclemente114 to assess whether or not patients 
are willing to consider the negative effects of opioids on their 
lives, as well as their willingness to engage in other forms 
of therapy to reduce their reliance on opioid medications 
effectively. By assessing patients with possible comorbid 
pain and addiction using this approach, it provides patients 
with an empathetic, nonjudgmental platform to discuss the 
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patient’s concerns about their medication use/abuse and to 
identify if their use of opioids allows them to meet their 
life goals.115 For those patients willing and able to identify 
the negative impact of opioids on their lives, referral to 
health psychologists (particularly those specializing in 
pain  management), physical therapists, and family system 
therapists would be appropriate.
Cognitive behavioral therapy
Using goal-focused integrated cognitive behavioral therapy, 
pain management, and opioid misuse treatment would focus 
on patient goals that link across both issues. Because the 
primary goal is to return the patient to as close to normal 
functioning as possible, a shared goal can be used as the 
focus of therapy sessions. Common subgoals to both pain116 
and substance abuse117 include: increased feelings of pain 
and craving self-efficacy; decreased reliance on chemical 
substances for relief; reduced anxiety and depression; 
increasing environmental stimulation to reduce focus on pain 
or substance use from boredom; resuming pleasant hobbies 
and activities; increased distress tolerance (eg, cravings, 
pain); and increased social support for healthy activities. 
Research suggests that cognitive behavioral therapy utilizing 
these or similar tools can be effective in reducing opioid 
use, even in the context of chronic pain. A 3-week intensive 
behaviorally-based pain program on opioid use showed that, at 
18-month follow-up, 123 patients not only used significantly 
less opioid medication (72% vs 24%), but also reported 
significantly lower pain levels (8.2/10 vs 4.2/10).118 Cognitive 
behavioral therapy and derivatives of cognitive behavioral 
therapy (such as acceptance and commitment therapy) are 
arguably the primary backbone of all current psychotherapy 
for either pain or addiction. Therefore, it is expected that any 
multidisciplinary treatment for comorbid pain and addiction 
would include a health psychologist trained in advanced 
cognitive behavioral therapy techniques.
Behavioral shaping
Used hand-in-hand with the previously described assessment 
of functioning, behavioral shaping can be used as a basis for 
helping patients resume a healthy lifestyle, and is arguably 
one of the most established treatments for chronic pain.119 
As the patient and physician relationship develops and it 
becomes clear that the patient is expected to participate in his/
her care (and not just be a passive recipient of medications), 
behavioral shaping can be a very powerful tool. Patients set 
small weekly or monthly behavioral goals that will help them 
move towards a healthy lifestyle. These are identifiable and 
measurable goals that can be monitored in the clinician’s 
office. As the patient re-engages with his/her daily activities 
he/she should be encouraged by the clinician and will likely 
be rewarded for increasing activities via increased social 
support, positive reinforcement by family members, more 
positive self-esteem, and a reduction in pain. As the patient’s 
focus shifts to external stimuli rather than maintaining a focus 
on their pain in the absence of any cognitive distractors, 
their pain experience will decrease. True behavioral shaping 
(or operant conditioning) includes material rewards as well 
(eg, tokens that can be redeemed for goods), and can be 
integrated into treatment plans for patients who are initially 
less intrinsically motivated. This technique in essence uses 
both operant conditioning and cognitive dissonance. Patients 
are rewarded (with materially or nonmaterial rewards) for 
“good” behaviors that they then desire to repeat. As patients 
continue to engage in positive behaviors, they also transfer the 
desire to engage in the behavior from “earning a reward” to an 
internally motivated drive.120 This has been used successfully 
to reduce pain reports, as well as opioid use.121 Usually this 
treatment is best integrated into a multidisciplinary treatment 
plan and should not be used as a stand-alone treatment 
device.122
Self-regulation therapy
Self-regulation therapy is found under many names in the 
research literature, including autogenic training, relaxation 
therapy, biofeedback, and imagery. Meta-analyses have 
shown that these forms of treatment rival pain reduction rates 
of opioid medication.123 This form of therapy is  frequently 
integrated with other psychosocial pain management 
strategies as one step to increasing patient self-efficacy. The 
health psychologist directing this therapy teaches patients to 
reduce their physiological reactivity to pain, cravings, and 
strong emotional states to improve the patient’s control over 
their pain experience.
Acupuncture
In 1998, the National Institutes of Health convened a 
conference to review the evidence on the eff icacy of 
acupuncture. At that time, it was recognized that sufficient 
evidence existed to endorse the complementary use of 
acupuncture to treat (among other things) chronic pain and 
substance abuse.124 Research has been somewhat limited in 
treating substance misuse in the context of chronic pain, but 
a meta-analysis of studies of acupuncture for chronic pain 
suggests a minimum of six treatments is needed to see a 
significant change in pain reports.125
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Spirituality
Integrating spiritual resources into treatment has been of 
increasing interest to researchers in the areas of both addiction 
and chronic pain. If patients have a faith background that can 
support them in reducing opioid use and improving pain 
management, clinicians should consider encouraging patients 
to use those resources. Many of those undergoing addiction 
treatment report that spirituality is a positive coping 
mechanism for them, and welcome integrating spirituality 
into treatment protocols.126 Prayer is one of the top pain-
coping strategies in the context of opioid dependence.127 
Additionally, research has shown that spirituality can be a 
powerful mechanism for chronic pain relief, and empirically 
validated treatments have been developed to help patients 
with chronic pain increase their self-efficacy and to improve 
their coping with pain.18
Meditation
Meditation techniques vary widely, and include mantram, 
transcendental meditation, loving-kindness, yoga, and tai 
chi. Meditation is well supported as a treatment of both 
pain and opioid addiction. While there is limited empirical 
data on using meditation to treat comorbid pain and opioid 
addiction, sufficient evidence exists for individual treatment 
of pain128–130 and addiction131 to warrant consideration.
Mindfulness
Like for meditation, there are a large number of mindfulness 
techniques which may be useful in treating polysubstance 
addiction132 and chronic pain.133,134 However, there appears to 
be a lack of quality studies specifically looking at the effect of 
mindfulness on opiate addiction and opioid misuse.135 There 
is a need for more research in this area.
Chronic pain support groups
Support groups can be very helpful for some individuals with 
chronic pain, and these groups are readily available via the 
Internet or phone. Support groups provide information and 
strategies to manage chronic pain. In addition to learning 
new skills and information, individuals can gain a sense 
of hope that others have been able to manage their chronic 
pain. They are able to manage the emotional struggles and 
spiritual suffering that chronic pain can cause better. Support 
groups can be safe places to share feelings and receive 
nonjudgmental acceptance and positive regard.136
There are a variety of types of support groups, including 
in-person, phone, and Internet options. Some meetings focus 
on general chronic pain and others focus on pain related to 
specific diseases, eg, arthritis, cancer, and fibromyalgia. 
Meetings can be led by experts or peers with chronic pain, be 
structured or unstructured, and focus on providing informa-
tion or social support, emotional support, or skills such as 
relaxation strategies. There are support groups that are mod-
eled on the 12-step peer support model similar to  Alcoholics 
Anonymous and other 12-step programs. Chronic Pain 
Anonymous is the prototype of adapting the 12-step model. 
Table 2 provides a list of support groups and other Internet 
resources that provide much more information.
The Internet is a window to many resources, includ-
ing some that are very reputable and helpful, but not all. 
The average person now seeks information on the Internet 
routinely and many have had the experience of joining chat 
rooms, blogs, list serves, and message boards. However, there 
continue to be individuals who will need encouragement to 
consider this source of information and support. Less Inter-
net-savvy individuals will likely need specific recommenda-
tions for Internet groups, as well as ongoing encouragement 
and conversation about their efforts to connect with support 
groups. Clinicians might consider giving out the information 
from Martelli et al137 who provide an introductory guide to 
chronic pain resources on the Internet.
Some advantages to online support groups are that there 
is no cost, they are easy to access, are available 24 hours and 
7 days per week, and allow individuals to remain anonymous. 
There are advantages to in-person meetings for those indi-
viduals who prefer in-person conversations, including more 
indepth conversation, and a quicker sense of connection with 
others. Patients can benefit from discussing the options with 
their clinicians.
The American Chronic Pain Association has helpful infor-
mation on their website to prepare individuals to participate 
in support groups. This organization also has a 10-step guide 
available which is designed to help people deal better with 
their pain and improve the quality of their lives. The 10-step 
Table 2 Chronic pain support groups and internet resources
American Academy of Pain Medicine www.painmed.org
American Chronic Pain Association www.theacpa.org
American Pain Foundation www.painfoundation.org
Chronic Pain Anonymous www.chronicpainanonymous.org
Chronic Pain Support www.chronicpainsupport.org/
support.html
National Chronic Pain Outreach 
Association
www.chronicpain.org
National Chronic Pain Society www.ncps-cpr.org/
supportgroups
National Pain Foundation www.nationalpainfoundation.org/
community.php
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guide is quite different from the 12-step model of Chronic 
Pain Anonymous. The 10-steps include accepting the pain, 
getting involved in one’s own health care, learning to set 
priorities, setting realistic goals, knowing that one has a 
basic right to be respected, recognizing that emotions affect 
physical wellbeing, learning to relax, exercising, seeing the 
total picture, and reaching out to share with others.138
The 12-step approach is based in spiritual healing and the 
power of the support group (ie, “fellowship”). The 12-step 
program begins by encouraging individuals to accept that their 
life has become unmanageable due to chronic pain (acceptance 
step) and that individuals are powerless to cure the physiology 
of the pain but do have the ability to control their reaction to 
the pain. The emphasis on spirituality is the cornerstone to this 
approach. For many with chronic pain this is very important 
and often not a part of traditional medical treatment. Some 
individuals with chronic pain are angry at their God and feel 
betrayed in that relationship (“Why me? How could God have 
allowed this to happen to me?”). The 12-step approach can 
ultimately be very helpful for these individuals.
In summary, clinicians should be aware of the wide 
range of support groups and community resources available, 
provide this information to patients, and include discussions 
and recommendations for their patients. Continuing to follow 
up on their interest and ability to engage in support groups 
is important.
Diversion
Diversion of opioid analgesics from legitimate to nonmedical 
use is on the increase.14 At present, prescription opioid 
analgesics are the most commonly abused prescription 
medications in the US. Drug diversion occurs at every 
point in the drug supply chain, ie, at the level of distribution 
because of theft, at the retail level with the sale of controlled 
substances without prescriptions, the use of stolen or forged 
prescriptions, theft from pharmacies or health care facilities, 
at the patient level with inappropriate prescribing, and the 
seeking of prescription drugs under false pretenses. The 
improper disposal, sale, or gifting of legitimately prescribed 
medications also contributes to the pool of diverted drugs.
People divert opioid analgesics for a variety of reasons. 
Although some divert drugs for monetary gain, other 
individuals may use the illegally acquired drugs themselves. 
Other nonmedical uses of prescription drugs include 
exploratory behavior, compulsive use, self-medicating for 
mood, sleep, or pain, and to alleviate abstinence symptoms. 
The relationship between increased opioid prescribing and the 
misuse of opioids is unclear. For example, prescription drug 
users are less likely to obtain prescription opioids for euphoria 
than for pain, and those who do use opioid analgesics for 
euphoria usually purchase these drugs from dealers.139
State-level interventions to address 
misuse of prescription drugs
Due to the high rates of both chronic pain and prescription 
drug misuse, state-level interventions have developed over 
the past 50 years, including requiring continuing medical 
education credits on these topics, providing guidelines and 
other resources for prescribers, and the development of 
 prescription monitoring programs. These state-level interven-
tions target the wide range of prescribers (see Table 3).
Some states have very helpful websites that provide 
information for prescribers. An example is the Massachusetts 
Pain Initiative (www.masspaininitiative.org). This website 
provides information and downloadable PDFs including a 
pain resource guide, newsletter, screening tools, and pocket 
pain management tool. Another state providing helpful 
information is Oregon (http://www.oregon.gov/OHA/OHPR/
PMC/index.shtml/), which supplies policy information and 
educational materials.
Washington State has an online resource guideline on 
the use of opioids for chronic noncancer pain. The guideline 
was developed by experts in the field on behalf of the state’s 
Agency Medical Directors Group. The guideline includes 
other resources and tools to educate prescribers. In addition, 
the site has free continuing medical education credits (www.
agencymeddirectors.wa.gov/). California and Oregon 
are examples of states that have gone beyond providing 
information, in that they require their prescribers to take a 
specific number of continuing medical education credits on 
chronic pain and pain management.
State prescription monitoring programs have been 
implemented in about 50% of states, and are being devel-
oped or considered in another 25% of states.140 These pro-
grams include prevention, intervention, investigation, and 
enforcement. They were developed to reduce the likelihood of 
drug diversion by prescribers, doctor shopping, and fraud, and 
to prevent unnecessary deaths and injuries associated with use 
Table 3 State-level resources
Massachusetts Pain initiative www.masspaininitiative.org
Oregon Pain Management 
Commission
www.oregon.gov/OHA/OHPR/PMC/
index.shtml/
Washington Agency Medical 
Directors Group
www.agencymeddirectors.wa.gov/
Alliance of State Pain initiatives http://trc.wisc.edu/
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of prescription medications for pain management. Prescrip-
tion monitoring programs can track data from pharmacies 
and provide prescribers with more complete information 
about patient use of controlled substances (patient activity 
reports). They can provide statistical reports to follow state 
trends and create collaborations with other state agencies and 
programs. In 2003, the Drug Enforcement Administration 
and the Department of Justice initiated a competitive grant 
program that attempted to encourage more states to create 
prescription monitoring programs. At that time, there were 
about 15 states with prescription monitoring programs. The 
program was very successful in encouraging other states. Of 
note, in the past, another source of support for prescription 
monitoring programs at the state level was the National All 
Schedules Prescription Electronic Reporting Act of 2005. 
However, this source has not continued.
Evaluations of the programs suggest that they are effective, 
particularly in the overall reduction of prescription of pain 
management medications and also in increasing physician 
awareness of this issue. More research is needed. Some of the 
prescription monitoring programs are not proactive and only 
provide information when asked. There is a range of medi-
cations that the different prescription monitoring programs 
monitor in different states (many focus on Schedule IV and/
or Schedule III medications) and most of the misused medica-
tions are in Schedule III. The National Alliance For Model 
State Drug Laws provides updates on these programs. Another 
source of information on prescription monitoring programs 
is on the Alliance of State Pain Initiatives website (http://trc.
wisc.edu/), which has an informative position paper.
Another state level intervention is creating policies that 
define what an addiction is. There is great variability amongst 
states, and this topic is important to distinguish between 
physical dependence that can occur even with appropriate 
prescribing and taking of these medications. Patients with 
substance use disorders are at high risk of chronic trauma-
induced pain and do need acute pain management. These 
definitions can sometimes lead to reduced quality of care for 
this population, which is of course weighed against the issue 
of misuse of prescription pain relief medications.
US Food and Drug Administration
In response to the current epidemic of opioid-related deaths, 
the FDA intends to require opioid manufacturers to provide 
training for both clinicians and patients on the appropriate 
prescribing and use of opioid analgesics. However, in July 
2010, an advisory panel (comprising the Anesthetic and Life 
Support Drugs Advisory Committee and Drug Safety and 
Risk Management Advisory Committee) rejected the FDA 
risk evaluation and mitigation strategy (REMS). The major-
ity of members noted that the proposed REMS simply did 
not go far enough. The REMS, which was proposed to apply 
solely to long-acting opioid analgesics, should be extended 
to all opioids, irrespective of the setting in which they are 
prescribed. In addition to making pain management training 
mandatory for any clinicians seeking a Drug Enforcement 
Administration number, the advisory panel indicated that 
patients should bear a greater burden of responsibility for 
their own treatment. Committee recommendations included 
registration of patients who receive long-term opioid therapy 
and signing treatment agreements. While the final FDA deci-
sion on its REMS is not available, the response to opioid 
abuse and unintentional death will likely have an impact on 
patients and providers alike.
Conclusion
Opioid analgesic abuse in the context of chronic pain treat-
ment can be a complex issue. This issue is gaining an increas-
ing amount of attention on an international scale. While 
researchers are scrambling to identify empirically validated 
treatment options across the pharmacological, psychological, 
and social domains; governmental legislators and state medi-
cal boards are attempting to implement programs to increase 
education for providers and reduce diversion. Despite this 
recent attention, a number of serious challenges remain in 
the treatment of chronic pain in the context of opioid misuse. 
There are many treatments that have not been empirically 
validated, there are challenges to using methadone and 
buprenorphine to treat comorbid pain and addiction, and 
there are limited educational opportunities for physicians 
and psychologists who wish to treat patients with chronic 
pain and opioid misuse. As the field continues to develop 
strong integrated psychological-pharmacological treatment 
paradigms, it is hoped that we can reduce the instances of 
misuse and prevent many cases from progressing to the level 
of comorbid addiction.
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